Clinical Trial Update: HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates perioperative use of hepatic arterial infusion chemotherapy combined with donafenib and sintilimab for patients with resectable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Hepato Cellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING